[HTML][HTML] Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review

SR Smith, BR Deshpande, JE Collins, JN Katz… - Osteoarthritis and …, 2016 - Elsevier
Objective Summarize the comparative effectiveness of oral non-steroidal anti-inflammatory
drugs (NSAIDs) and opioids in reducing knee osteoarthritis (OA) pain. Methods Two …

Celecoxib for osteoarthritis

L Puljak, A Marin, D Vrdoljak, F Markotic… - Cochrane Database …, 2017 - cochranelibrary.com
Background Osteoarthritis (OA) is the most common form of arthritis and is caused by
degeneration of the joint cartilage and growth of new bone, cartilage and connective tissue …

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

DO Clegg, DJ Reda, CL Harris, MA Klein… - … England Journal of …, 2006 - Mass Medical Soc
Background Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The
multicenter, double-blind, placebo-and celecoxib-controlled Glucosamine/chondroitin …

Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials

JM Bjordal, A Klovning, AE Ljunggren… - European Journal of Pain, 2007 - Elsevier
BACKGROUND: Pain is the most debilitating symptom in osteoarthritis of the knee (OAK).
AIM AND METHODS: To determine the short-term pain-relieving effects of seven commonly …

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

J Zhang, EL Ding, Y Song - Jama, 2006 - jamanetwork.com
ContextAdverse effects of selective cyclooxygenase 2 (COX-2) inhibitors on renal events
and arrhythmia have been controversial, with suggestions of a class effect. ObjectiveTo …

Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials

RR Bannuru, TE McAlindon, MC Sullivan… - Annals of internal …, 2015 - acpjournals.org
Background: Placebo controls are essential in evaluating the effectiveness of medical
treatments. Although it is unclear whether different placebo interventions for osteoarthritis …

Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis

PL McCormack - Drugs, 2011 - Springer
Celecoxib (Celebrex®) was the first cyclo-oxygenase (COX)-2 selective inhibitor (coxib) to
be introduced into clinical practice. Coxibs were developed to provide anti-inflammatory …

Safety of cyclooxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis

E Curtis, N Fuggle, S Shaw, L Spooner, G Ntani… - Drugs & aging, 2019 - Springer
Objective Our aim was to assess the safety of cyclooxygenase-2 (COX-2) inhibitors in the
management of osteoarthritis (OA) in a systematic review and meta-analysis of randomized …

Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review

A Rostom, K Muir, C Dubé, E Jolicoeur… - Clinical …, 2007 - Elsevier
Background & Aims: Nonselective non-steroidal anti-inflammatory drugs (NSAIDs) and
cyclooxygenase-2 inhibitors (COX-2s) are used to treat a variety of arthritic and inflammatory …

Clinical use and pharmacological properties of selective COX-2 inhibitors

S Shi, U Klotz - European journal of clinical pharmacology, 2008 - Springer
Abstract Selective COX-2 inhibitors (coxibs) are approved for the relief of acute pain and
symptoms of chronic inflammatory conditions such as osteoarthritis (OA) and rheumatoid …